# A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

> **NCT04225117** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 329 (actual)

## Conditions studied

- Locally Advanced or Metastatic Malignant Solid Tumors

## Interventions

- **DRUG:** enfortumab vedotin
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04225117
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-10
- **Primary completion:** 2025-02-25
- **Final completion:** 2026-09-30
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225117, "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04225117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*